Self Double-stranded (ds)DNA Induces IL-1β Production from Human Monocytes by Activating NLRP3 Inflammasome in the Presence of Anti-dsDNA Antibodies
Overview
Authors
Affiliations
The pathogenic hallmark of systemic lupus erythematosus is the autoimmune response against self nuclear Ags, including dsDNA. The increased expression of the proinflammatory cytokine IL-1β has been found in the cutaneous lesion and PBMCs from lupus patients, suggesting a potential involvement of this cytokine in the pathogenesis of lupus. IL-1β is produced primarily by innate immune cells such as monocytes and can promote a Th17 cell response, which is increased in lupus. IL-1β production requires cleaving pro-IL-β into IL-1β by the caspase-1-associated multiprotein complex called inflammasomes. In this study we show that self dsDNA induces IL-1β production from human monocytes dependent on serum or purified IgG containing anti-dsDNA Abs by activating the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. Reactive oxygen species (ROS) and K(+) efflux were involved in this activation. Knocking down the NLRP3 or inhibiting caspase-1, ROS, and K(+) efflux decreased IL-1β production. Supernatants from monocytes treated with a combination of self dsDNA and anti-dsDNA Ab(+) serum promoted IL-17 production from CD4(+) T cells in an IL-1β-dependent manner. These findings provide new insights in lupus pathogenesis by demonstrating that self dsDNA together with its autoantibodies induces IL-1β production from human monocytes by activating the NLRP3 inflammasome through inducing ROS synthesis and K(+) efflux, leading to the increased Th17 cell response.
Sircana M, Erre G, Castagna F, Manetti R Life (Basel). 2024; 14(6).
PMID: 38929699 PMC: 11204900. DOI: 10.3390/life14060716.
Pisetsky D Arthritis Rheumatol. 2024; 76(9):1334-1343.
PMID: 38622070 PMC: 11349482. DOI: 10.1002/art.42863.
Heil M Front Immunol. 2024; 14:1259879.
PMID: 38439942 PMC: 10910434. DOI: 10.3389/fimmu.2023.1259879.
The role of inflammasomes in human diseases and their potential as therapeutic targets.
Yao J, Sterling K, Wang Z, Zhang Y, Song W Signal Transduct Target Ther. 2024; 9(1):10.
PMID: 38177104 PMC: 10766654. DOI: 10.1038/s41392-023-01687-y.
New Potentiality of Bioactive Substances: Regulating the NLRP3 Inflammasome in Autoimmune Diseases.
Chen B, Wang Y, Chen G Nutrients. 2023; 15(21).
PMID: 37960237 PMC: 10650318. DOI: 10.3390/nu15214584.